Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Truseltiq |
|---|---|
| Manufacturer | QED Therapeutics, Inc |
| Prescription required | Yes |
Truseltiq Capsules 42 x 125mg(infigratinib)
infigratinib
Description
Truseltiq Capsules 42 x 125mg(infigratinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: infigratinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: QED Therapeutics, Inc. Therapeutic category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Pack information: 125 / 42. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Infigratinib is an FGFR inhibitor formerly used for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement where available.How to Use
Use infigratinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: infigratinib. Pack size: 125 / 42. Pack unit: box. Manufacturer: QED Therapeutics, Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.